Pfizer said Chief Financial Officer Dave Denton will step down on Aug. 15 and leave the company for a consumer-goods role, ending a finance tenure that included the Seagen, Biohaven and Metsera transactions.
The company named Cecile Guegan, currently senior vice president of finance for its global biopharmaceutical business, as interim CFO effective Aug. 16 while it conducts an internal and external search for a permanent replacement.
Guegan has been with Pfizer for more than 20 years and currently oversees the financial operations and reporting for the company’s biopharmaceutical business across all therapeutic areas and geographies. Pfizer said she also led the integration of Seagen into the company in 2024.
Denton’s exit comes after a period in which Pfizer highlighted major deal activity under his watch, including Seagen, Biohaven and Metsera. The company said he and Guegan will work together on the transition before he leaves.
Pfizer did not announce any change to its broader financial targets, but the transition shifts day-to-day finance leadership to Guegan as the company looks to stabilize the role after a string of large portfolio moves. Today the company's shares have moved -3.05% to a price of $25.13. For more information, read the company's full 8-K submission here.
